US5593971A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for preventing onset of hypertension employing a cholesterol lowering drug
Assignee: ER Squibb and Sons LLC
•
Filing: 1995-05-22
•
Granted: 1997-01-14
•
Expires: 2015-05-22
Abstract
Abstract A method is provided for preventing or reducing the risk of hypertension in normotensive patients having insulin resistance by administering a cholesterol lowering drug, such as pravastatin, alone or in combination with an ACE inhibitor, especially one containing a mercapto moiety, such as captopril or zofenopril.
Inventors
- 👤 Werner Tschollar
- 👤 Cary S. Yonce
- 👤 James L. Bergey
- 👤 James C. Kawano
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:40
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/40; A61K31/095; A61K31/10; A61K31/185; A61K31/19; A61K31/21; A61K31/215; A61K31/22; A61K31/335; A61K31/365; A61K31/66; A61K38/00; A61K38/16; A61K38/55; A61K38/556
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
58 words
A method for treating a normotensive mammalian species having insulin resistance to inhibit hypertension, which comprises administering to a mammalian species in need of such treatment an effective amount of a cholesterol lowering drug which is a fibric acid derivative, probucol, dextrothyroxine or its sodium salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicylic acid or aspirin.
Claim 2
Independent Claim
58 words
A method for treating a normotensive mammalian species having insulin resistance to inhibit hypertension, which comprises administering to a mammalian species in need of such treatment an effective amount of a cholesterol lowering drug which is a fibric acid derivative, probucol, dextrothyroxine or its sodium salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicylic acid or aspirin.
Claim 3
Dependent Claim
26 words
The method as defined in claim 1 wherein the cholesterol lowering drug is a fibric acid derivative which is gemfibrozil, fenofibrate, clofibrate, bezafibrate, ciprofibrate or clinofibrate.
Claim 4
Dependent Claim
33 words
The method as defined in claim 1, wherein said cholesterol lowering drug is probucol, gemfibrozil, clofibrate, dextrothyroxine or its sodium salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicylic acid or aspirin.
Claim 5
Independent Claim
71 words
A method for treating a normotensive mammalian species having insulin resistance to inhibit hypertension, which comprises administering to a normotensive mammalian species in need of such treatment a combination of an effective amount of cholesterol lowering drug which is a fibric acid derivative, probucol, dextrothyroxine or its sodium salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicyclic acid or aspirin, and an effective amount of an angiotensin converting enzyme inhibitor.
Claim 6
Independent Claim
71 words
A method for treating a normotensive mammalian species having insulin resistance to inhibit hypertension, which comprises administering to a normotensive mammalian species in need of such treatment a combination of an effective amount of cholesterol lowering drug which is a fibric acid derivative, probucol, dextrothyroxine or its sodium salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicyclic acid or aspirin, and an effective amount of an angiotensin converting enzyme inhibitor.
Claim 7
Dependent Claim
18 words
The method as defined in claim 4 wherein the angiotensin converting enzyme inhibitior is a substituted proline derivative.
Claim 8
Dependent Claim
23 words
The method as defined in claim 4 wherein said angiotensin converting enzyme inhibitor includes a mercapto moiety and is a substituted proline derivative.
Claim 9
Dependent Claim
22 words
The method as defined in claim 4 wherein said angiotensin converting enzyme inhibitor is captopril, zofenopril, enalapril, cernapril, fosinopril, lisinopril or fentiapril.
Claim 10
Dependent Claim
50 words
The method as defined in claim 4 wherein the angiotensin converting enzyme inhibitor is a phosphonate substituted amino or imino acid or salt thereof, a proline derivative, a substituted proline derivative, a mercaptoacyl derivative of a substituted proline, a carboxyalkyl dipeptide derivative, a phosphinylalkanoyl proline derivative or a phosphonamidate derivative.
Claim 11
Dependent Claim
18 words
The method as defined in claim 8 wherein said angiotensin converting enzyme inhibitor is a carboxyalkyl dipeptide derivative.
Claim 12
Dependent Claim
32 words
The method as defined in claim 4 wherein said angiotensin converting enzyme inhibitor is a phosphinylalkanoyl proline derivative, a phosphoramidate derivative, or a phosphonate substituted amino or imino acid or salt thereof.
Claim 13
Dependent Claim
33 words
The method as defined in claim 4 wherein the cholesterol lowering drug is present in a weight ratio to said ACE inhibitor of within the range of from about 0,001:1 to about 1000:1.
Claim 14
Dependent Claim
32 words
The method as defined in claim 4 wherein said angiotensin converting enzyme inhibitor is administered in single or divided doses of from about 0.1 to about 500 mg/one to four times daily.
Claim 15
Dependent Claim
26 words
The method as defined in claim 4 wherein the cholesterol lowering drug is a fibric acid derivative and the ACE inhibitor is captopril, fosinopril or ceranapril.
Claim 16
Dependent Claim
23 words
The method as defined in claim 4 wherein the ACE inhibitor is administered in an amount below that required to cause hemodynamic effects.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-01-14 | 2000-07-15 | 2001-01-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-01-14 | 2004-07-15 | 2005-01-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-01-14 | 2008-07-15 | 2009-01-14 | $7700.00 | Window Closed / Lapsed |